Maraviroc is a CCR5 antagonist approved to treat adults infected with CCR5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics, safety, and efficacy of maraviroc in combination with optimized background therapy (OBT) in treatment-experienced pediatric patients infected with R5 HIV-1 and support registration of maraviroc for pediatric use.
Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
Giaquinto, Carlo
;
2017
Abstract
Maraviroc is a CCR5 antagonist approved to treat adults infected with CCR5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics, safety, and efficacy of maraviroc in combination with optimized background therapy (OBT) in treatment-experienced pediatric patients infected with R5 HIV-1 and support registration of maraviroc for pediatric use.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
